



Silence Therapeutics Appoints Financial Adviser and Broker and Nominated Adviser

London, UK, 20th November 2007 - Silence Therapeutics plc (LSE: SLN) ("the Company"), a leading European RNAi therapeutics company, announces the appointment of Lazard as its financial adviser and Nomura Code Securities Limited ("Nomura Code") as its broker and nominated adviser with immediate effect.

Silence Therapeutics has appointed these new advisers to support the Company through its next stage of development and growth, which is being driven by its recently appointed Chief Executive Officer, Jeff Vick, who joined in July 2007. Silence Therapeutics' goal is to become a global leader in RNAi therapeutics based on its novel, stabilised, blunt-ended AtuRNAi[®] molecules and its AtuPlex[®], drug delivery technology. Silence Therapeutics' growth strategy is centred on further RNAi collaborations, which gives its partners access to the Company's unique technology on a target specific basis, progressing its internal pipeline of AtuRNAi therapeutics and expanding its patent estate around its unique RNAi and drug delivery technologies. In this regard, Silence Therapeutics is continuing to work with the US Patent Office on its core AtuRNAi patent application and remains confident that it will be allowed in due course. The Company's core AtuRNAi patent was granted in Europe earlier this year.

Jeffery S. Vick, Chief Executive Officer of Silence Therapeutics, commented: "We are pleased to announce the appointments of our new financial adviser and our new broker and nominated adviser to provide a world-class level of support as we execute our ambitious corporate strategy. As our recent deal with AstraZeneca illustrates, Silence Therapeutics operates in one of the most exciting areas of the pharmaceutical industry. With the advice and support of Lazard and Nomura Code, we will build on the significant progress we have made over the last year to become one of the global leaders in the RNAi space."

- Ends -

Enquiries:

For further information, please contact the following:

Silence Therapeutics plc

+44(0)20 7307 1620
Jeff Vick, CEO
Melvyn Davies, FD

Citigate Dewe Rogerson

+44(0)20 7638 9571
David Dible
Yvonne Alexander

Nomura Code Securities Limited

+44(0)20 7776 1200
Chris Collins
Gerard Harper

Notes to Editors

Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (LSE:SLN) is a leading RNAi company. RNA interference (RNAi) can selectively 'silence' genes linked to the onset of disease.

Silence Therapeutics has developed novel, proprietary short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

In July 2007, Silence Therapeutics formed a research and development collaboration with AstraZeneca to develop AtuRNAi against five specific targets including those in respiratory indications. The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound AKli-5. This compound is in a Phase I human clinical study for treatment of acute kidney injury. In addition, Silence Therapeutics expects to begin the clinical development of its own proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2008.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About RNAi

RNA interference (RNAi), a Nobel Prize winning technology, is one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.